Updated for the first time since 2014, ACOG’s guidance covers hormone and nonhormonal treatments, supplements, therapy and lifestyle approaches.
ACOG’s first menopause guidance update since 2014 gives clinicians a broader set of options for addressing hot flashes, sleep disruption and mood changes. The shift matters because symptoms often overlap, and the best treatment can depend on a patient’s health history, preferences and which problems are affecting daily life.
The American College of Obstetricians and Gynecologists published its updated guidance on menopause related vasomotor, sleep and mood symptoms in 2026. It covers medication as well as behavioral and lifestyle approaches, framing menopause care as a set of choices to discuss with a clinician rather than a single standard regimen.
Hormone therapy remains an option, with timing in view
Menopausal hormone therapy (MHT) is among the most effective treatments for hot flashes and night sweats, symptoms that can also interfere with sleep. ACOG says treatment is generally most beneficial when started before age 60 or within 10 years of natural menopause.
That timing is one factor in a personal risk and benefit discussion. MHT may not be appropriate for some people, including those with a history of stroke or certain forms of breast cancer. A clinician can help weigh those considerations alongside symptom severity and medical history.
For people who don’t want hormone therapy or aren’t suitable candidates, the guidance includes several nonhormonal medications. SSRIs and SNRIs, classes of antidepressants, can reduce hot flashes even when depression isn’t being treated. Gabapentin may be considered when other nonhormonal options aren’t effective or cause difficult side effects.
One notable addition is the class of neurokinin receptor antagonists. Fezolinetant, sold as Veozah, and elinzanetant, sold as Lynkuet, act on the brain’s temperature regulation system and can help reduce hot flashes and related sleep disruption.
Supplements don’t have the same evidence base
Menopause products containing soy isoflavones, black cohosh and other herbs are widely marketed, but ACOG says current evidence doesn’t establish their safety or effectiveness for hot flashes and other menopause symptoms. The guidance also points out that supplements don’t require FDA approval before reaching the market, so they may not have been tested for purity, safety or efficacy.
That doesn’t establish that every supplement is harmful. It does mean “natural” shouldn’t be treated as proof that a product works or is safe. Patients should tell their clinician about supplements they use or are considering, particularly when they take other medications.
Behavioral approaches can be part of care
ACOG also includes cognitive behavioral therapy (CBT), which can help with sleep and mood by changing patterns of thought and responses to symptoms. Mindfulness practices and regular exercise may help with sleep problems and mood changes, while clinical hypnosis and acupuncture are also listed as non-drug options.
These approaches may complement medication or, depending on the person’s symptoms and preferences, serve as alternatives. The practical point is to discuss major treatment changes with a clinician and build a plan around the symptoms that matter most.
Make the next appointment specific
Menopause symptoms can affect sleep, work, relationships and everyday routines. A symptom journal can give a clinician a clearer picture: record how often symptoms occur, how intense they are, their effect on daily life, and any changes in period length or flow.
Patients should also share relevant personal and family medical history, especially heart disease, stroke, blood clots or breast cancer. Asking about hormone therapy, nonhormonal medication and supportive approaches such as CBT or mindfulness can make the discussion more useful. Scheduling a follow-up before leaving the appointment can help keep care on track.
ACOG’s update recognizes that menopause symptoms and access to care vary across individuals, including across cultural, socioeconomic and ethnic groups. The guidance offers a starting point for a more informed conversation: identify the symptoms disrupting life, bring relevant history, and work with a clinician to choose an approach that fits.
Discussion
Sign in to join the discussion.